TRANSCENTA Group released clinical trial research results for the Osemitamab triple therapy

Transcenta Group (06628.HK) announced that its humanized monoclonal antibody Osemitamab (TST001), targeting CLDN18.2, in combination with Nivolumab and CAPOX, is undergoing a Phase I/II clinical trial as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma. The updated efficacy analysis based on CLDN18.2 and PD-L1 expression from the G cohort will be presented at the European Society for Medical Oncology Asia Annual Meeting.

Qichuan, Executive Vice President of Global Clinical Development at Transcenta, stated that the study continues to show strong clinical benefit signals, further confirming the potential of Osemitamab to provide substantial benefits to patients. The updated data also confirms that the Osemitamab combination therapy has good safety and tolerability as a first-line treatment option for advanced gastric or gastroesophageal junction adenocarcinoma